Financial reports
10-K/A
2023 FY
Annual report (amended)
26 Apr 24
10-K
2023 FY
Annual report
22 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
10-K
2022 FY
Annual report
22 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
10-K
2021 FY
Annual report
24 Mar 22
Current reports
8-K
Regulation FD Disclosure
25 Apr 24
8-K
Regulation FD Disclosure
18 Apr 24
8-K
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
10 Apr 24
8-K
Other Events
8 Apr 24
8-K
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
27 Mar 24
8-K
Regulation FD Disclosure
25 Mar 24
8-K
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
25 Mar 24
8-K
Moleculin Reports Full Year 2023 Financial Results
22 Mar 24
8-K
Guidance to be provided for clinical development strategy for advancement of Annamycin into potential AML pivotal registration study
20 Mar 24
8-K
Moleculin Announces Reverse Stock Split
19 Mar 24
Registration and prospectus
424B3
Prospectus supplement
16 Feb 24
S-1
IPO registration
2 Feb 24
424B5
Prospectus supplement for primary offering
22 Dec 23
S-8
Registration of securities for employees
21 Jun 23
S-8
Registration of securities for employees
19 Jul 22
424B5
Prospectus supplement for primary offering
25 Jun 21
424B5
Prospectus supplement for primary offering
25 Jun 21
S-3
Shelf registration
28 May 21
424B5
Prospectus supplement for primary offering
4 Feb 21
S-3MEF
Registration of additional securities for an S-3
2 Feb 21
Proxies
DEF 14A
Definitive proxy
16 Jan 24
PRE 14A
Preliminary proxy
5 Jan 24
DEF 14A
Definitive proxy
1 Sep 23
PRE 14A
Preliminary proxy
21 Aug 23
DEFA14A
Additional proxy soliciting materials
7 Jun 23
DEFA14A
Additional proxy soliciting materials
30 May 23
DEFA14A
Additional proxy soliciting materials
12 May 23
DEFA14A
Additional proxy soliciting materials
13 Apr 23
DEF 14A
Definitive proxy
13 Apr 23
PRE 14A
Preliminary proxy
3 Apr 23
Other
EFFECT
Notice of effectiveness
13 Feb 24
CORRESP
Correspondence with SEC
9 Feb 24
UPLOAD
Letter from SEC
9 Feb 24
EFFECT
Notice of effectiveness
14 Jun 21
CORRESP
Correspondence with SEC
9 Jun 21
UPLOAD
Letter from SEC
4 Jun 21
EFFECT
Notice of effectiveness
10 Apr 20
CORRESP
Correspondence with SEC
7 Apr 20
CORRESP
Correspondence with SEC
7 Jan 20
UPLOAD
Letter from SEC
6 Jan 20
Ownership